misses the key fi nding of our study: community-wide treatment is highly cost eff ective in many settings, even when elimination is not reached, because of the significant averted morbidity, both in children and adults. 1 The ability of mass drug administration to eliminate schistosomiasis and soiltransmitted helminthiasis has not yet been satisfactorily proven, and countries will need to make funding decisions without knowing whether elimination-or just control-will be achieved. To put these eff orts against one another is unproductive and not based on evidence.
When infected human populationswhether preschool-aged children or adults-remain untreated, they act as a hidden reservoir and continue to drive reinfection. We have shown that expanded community-wide treatment against schistosomiasis and soiltransmitted helminthiasis addresses this hidden reservoir, decreases overall disease transmission, and is highly cost eff ective. Global guidelines should be re-examined to address this important fi nding.
We declare no competing interests. 
Cost-eff ectiveness of community-wide treatment for helminthiasis Authors' reply
We are delighted by the interest in our study of the cost-effectiveness of expanded community-wide treatment against schistosomiasis and soil-transmitted helminthiasis.
1
In response to the critique by Hugo Turner and colleagues, we off er the following points for consideration. First, the use of binary disability weights for schistosomiasis is conservative, standard practice, and used by the Global Burden of Diseases study, 2 among others. Although we agree that better data is needed to inform disability as a function of schistosomiasis burden, we employed these conventional disability weights because such data are limited and we recognised disability even at low disease burden. 3 Importantly, the use of a binary disability weight is in fact conservative with respect to costeffectiveness, since no treatment benefit is given unless an infection is cured. Indeed, recalculation with intensity-stratifi ed disability weights reveals that community-wide treatment is even more cost eff ective (table; methods are further detailed in the appendix). 4, 5 Second, concern is raised over our use of a constant relation between parasitic worm burden and egg production from one helminth species to another. We tested alternative species-specific values for this poorly measured p arameter and found that our results are highly robust (appendix).
Taken together, the two methodological issues did not aff ect our results or conclusions.
Turner and colleagues further speculate that community-wide treatment might not be necessary in regions that are highly endemic for only Trichuris trichiura and Ascaris lumbricoides in school-aged children, which provides a hypothetical epidemiological situation to illustrate their argument. In reality, hookworm and schistosomiasiswith an age distribution that greatly affects adults-are frequently co-endemic with T trichiura and A lumbricoides. 6, 7 Furthermore, T trichiura and A lumbricoides do affect adult populations and are thus not confi ned to school-aged children alone, as shown by our use of real-world, age-structured data from four diverse epidemiological settings in Côte d'Ivoire.
1 Turner and colleagues miss another key message of the study: integration of mass drug administration (ie, giving albendazole with praziquantel) takes advantage of cost-efficiencies since most drugs are donated and the treatment cost is mostly for delivery. Integrated treatment should therefore almost always be considered in co-endemic settings, and integration in co-endemic settings should be considered in future studies of community-wide treatment with albendazole alone. 8 We are disappointed with the unsupported assertion that community-wide treatment will only be beneficial when elimination is reached. This outcome has not been shown in empirical studies and
Binary weight Stratifi ed weights
School-aged children* 118 98
Community-wide † 167 145
DALY=disability-adjusted life year. A lower incremental cost-eff ectiveness ratio is more cost eff ective, and an intervention was considered highly cost eff ective if the incremental cost-eff ectiveness ratio was less than US$1521 per DALY. *Relative to no treatment. †Relative to treatment of school-aged children.
Table:
Incremental cost-eff ectiveness ratio (US$ per DALY averted) of strategies for integrated mass drug administration targeting schistosomiasis and soil-transmitted helminthiasis using intensity-stratifi ed disability weight for schistosomiasis
